Abstract
Ovarian cancer is the most lethal gynecological oncological condition. He responds to primary surgical treatment, although the vast majority of patients are diagnosed in advanced stages of the disease, in which the rate of recurrences is increased and the chance of survival at 5 years is below 45%.
Highlights
The subject of early detection of ovarian cancer has been widely studied worldwide lately, no diagnostic method has yet been found to help diagnose early stages of the disease, so that patients come to the doctor when the abdomen is enlarged, already signify an advanced stage of the disease
In Japan, at the 4th edition of the meeting of the Japanese Society of Gynecological Oncology in 2015, in which the options for improving the prognosis of ovarian cancer were discussed, it was established that the primary treatment of epithelial ovarian cancer should be surgical: Intraoperative staging and Surgical eradication (Staging and Debulking), followed by adjuvant chemotherapy treatment, with appropriate follow-up [3]
According to the latest trials of patients studied, it was established that patients with operable disease per-primam and with good general status should benefit from primary cytoreductive surgical treatment, and patients with biological status affected or with the disease advanced disseminated will benefit from chemotherapy per primam, followed by interval surgery [5]
Summary
The subject of early detection of ovarian cancer has been widely studied worldwide lately, no diagnostic method has yet been found to help diagnose early stages of the disease, so that patients come to the doctor when the abdomen is enlarged (due to the presence of the ascites), already signify an advanced stage of the disease. The International Federation of OG recommends the extraction of the intact tumor - Total hysterectomy with bilateral anexectomy, infracolic omentectomy, pelvic and aortic lymphadenectomy and biopsy of any suspicious tumors. If it is necessary, it will can be performed hemicolectomies, peritonectomies and exenterations [4]. According to the latest trials of patients studied, it was established that patients with operable disease per-primam and with good general status should benefit from primary cytoreductive surgical treatment, and patients with biological status affected (associated comorbidities, modified bio-humoral balance) or with the disease advanced disseminated will benefit from chemotherapy per primam, followed by interval surgery [5]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call